Back to top

Azul's August Traffic & Load Factor Increase on Higher Demand

Read MoreHide Full Article

Azul S.A. (AZUL - Free Report) reported impressive traffic numbers for August. Consolidated traffic —   measured in revenue passenger kilometers (RPK) — increased 21.5% to 2.11 billion mainly owing to a 43.4% rise on the international front. Meanwhile, domestic traffic rose 14.6%. Traffic figures were aided by a strong demand for air travel.

On a year-over-year basis, consolidated capacity (or available seat kilometers/ASKs) expanded 20.3% to 2.57 billion primarily on account of 48% growth in international capacity. On the domestic front, capacity increased 12.5%.

In August, consolidated load factor (% of seats filled by passengers) at this Brazilian carrier inched up 0.8 percentage points to 82.4% as traffic growth outweighed capacity expansion. While the metric increased 1.5 percentage points to 81.2% domestically, it decreased 2.8 percentage points to 85.7% internationally.

AZUL SA Price

 

AZUL SA Price | AZUL SA Quote

 

At the end of the first eight months of 2018, RPK was up 17.1% and ASK grew 16.7%. Also, load factor for the period increased to 81.9%, 0.2 percentage points higher than the tally in August 2017. Notably, Azul posted results close on the heels of another Latin American carrier — Gol Linhas Aereas Inteligentes S.A. (GOL - Free Report) . GOL reported an increase in consolidated traffic but a decrease in load factor for the month.

Zacks Rank & Stocks to Consider

Azul carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader Transportation sector  are SkyWest, Inc. (SKYW - Free Report) and Trinity Industries, Inc. (TRN - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of SkyWest and Trinity have rallied more than 65% and 37%, respectively, in a year’s time.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>



More from Zacks Analyst Blog

You May Like